Ernst & Young has resigned as CANbridge Pharmaceuticals' (HKG:1228) auditor effective Friday, a same-day Hong Kong bourse filing said.
The move came about as the parties failed to reach an agreement on the audit fee for the year ending Dec. 31.
The biopharmaceutical company, on the same day, appointed HLB Hodgson Impey Cheng as its new auditor.
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.